Gusto Global utilizes proprietary technology that employs bacteria and fungi as biosensors to detect diseases, including cancer, at an earlier stage than traditional human biomarkers. Their microbiome therapeutics aim to restore healthy microbiome functionality, improving patient outcomes through targeted interventions.
Funding
$5.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods for detecting diseases like cancer often rely on human biomarkers, which may not identify the disease until it has progressed to a symptomatic stage. This late detection limits the window for effective intervention and can negatively impact patient outcomes.
Solution
Gusto Global is developing a platform that leverages bacteria and fungi as highly sensitive biosensors for early disease detection. Their proprietary technology uses microorganisms to identify diseases, including cancer, at earlier stages than traditional methods. By combining artificial intelligence with bacterial intelligence, Gusto Global aims to create microbiome therapeutics that restore healthy microbiome functionality and improve patient outcomes through targeted interventions. The company's approach opens the window for life-saving intervention by detecting diseases faster and more accurately.
Target Audience
The primary target audience includes healthcare providers, oncologists, and researchers focused on early disease detection and microbiome-based therapeutics.
Features
- Proprietary technology utilizing bacteria and fungi as biosensors
- Early detection of diseases, including cancer, before symptoms appear
- AI-driven analysis of microbiome data for improved accuracy
- Development of microbiome therapeutics to restore healthy functionality
- Targeted interventions to improve patient outcomes